Browse By

Global Blood Therapeutics Inc (GBT) Coverage Initiated by Analysts at SunTrust Banks, Inc.

Global Blood Therapeutics Inc logoSunTrust Banks, Inc. initiated coverage on shares of Global Blood Therapeutics Inc (NASDAQ:GBT) in a research note released on Monday, April 17th. The brokerage issued a buy rating and a $56.00 price target on the stock.

Other analysts also recently issued research reports about the company. Roth Capital set a $47.00 target price on Global Blood Therapeutics and gave the company a buy rating in a research note on Saturday, February 18th. Zacks Investment Research downgraded Global Blood Therapeutics from a buy rating to a hold rating in a research note on Tuesday, January 17th. JPMorgan Chase & Co. started coverage on Global Blood Therapeutics in a research note on Wednesday, January 4th. They set an overweight rating and a $25.00 target price for the company. Wedbush reaffirmed an outperform rating and issued a $73.00 price target on shares of Global Blood Therapeutics in a report on Monday, March 20th. Finally, Nomura started coverage on Global Blood Therapeutics in a report on Wednesday, March 1st. They issued a buy rating for the company. One research analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $50.37.

Shares of Global Blood Therapeutics (NASDAQ:GBT) traded up 0.50% during midday trading on Monday, reaching $29.90. 527,794 shares of the company traded hands. The stock’s 50-day moving average is $33.14 and its 200-day moving average is $23.21. Global Blood Therapeutics has a 1-year low of $13.35 and a 1-year high of $41.15.

Global Blood Therapeutics (NASDAQ:GBT) last announced its earnings results on Monday, May 1st. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.11. During the same period in the prior year, the company posted ($0.56) EPS. On average, equities analysts anticipate that Global Blood Therapeutics will post ($2.69) EPS for the current fiscal year.

WARNING: This piece was posted by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.com-unik.info/2017/05/07/global-blood-therapeutics-inc-gbt-coverage-initiated-by-analysts-at-suntrust-banks-inc-updated-updated.html.

In related news, major shareholder Robert I. Tepper sold 31,225 shares of the firm’s stock in a transaction on Thursday, April 6th. The stock was sold at an average price of $33.23, for a total transaction of $1,037,606.75. Following the completion of the sale, the insider now directly owns 229,773 shares of the company’s stock, valued at approximately $7,635,356.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.10% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. TLP Group LLC purchased a new position in shares of Global Blood Therapeutics during the third quarter worth approximately $111,000. Daiwa SB Investments Ltd. purchased a new position in shares of Global Blood Therapeutics during the first quarter worth approximately $120,000. Great West Life Assurance Co. Can purchased a new position in shares of Global Blood Therapeutics during the first quarter worth approximately $129,000. Bessemer Group Inc. purchased a new position in shares of Global Blood Therapeutics during the fourth quarter worth approximately $335,000. Finally, Teachers Advisors LLC raised its position in shares of Global Blood Therapeutics by 19.3% in the fourth quarter. Teachers Advisors LLC now owns 29,682 shares of the company’s stock worth $429,000 after buying an additional 4,812 shares during the last quarter. Hedge funds and other institutional investors own 56.36% of the company’s stock.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

5 Day Chart for NASDAQ:GBT

What are top analysts saying about Global Blood Therapeutics Inc? – Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Global Blood Therapeutics Inc and related companies.

Leave a Reply

Your email address will not be published. Required fields are marked *